Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cancer Vaccines | 34 | 2023 | 1023 | 7.800 |
Why?
|
Dendritic Cells | 43 | 2023 | 2725 | 4.170 |
Why?
|
Mucin-1 | 21 | 2017 | 543 | 4.060 |
Why?
|
Multiple Myeloma | 49 | 2023 | 5181 | 4.050 |
Why?
|
Immunotherapy | 22 | 2023 | 4445 | 2.220 |
Why?
|
Hematologic Neoplasms | 14 | 2021 | 1832 | 1.980 |
Why?
|
Hematopoietic Stem Cell Transplantation | 31 | 2023 | 5442 | 1.610 |
Why?
|
Leukemia, Myeloid, Acute | 15 | 2022 | 3523 | 1.550 |
Why?
|
Immunotherapy, Active | 3 | 2018 | 60 | 1.520 |
Why?
|
Immunotherapy, Adoptive | 14 | 2023 | 1270 | 1.390 |
Why?
|
Azacitidine | 3 | 2019 | 347 | 1.150 |
Why?
|
Cell Fusion | 12 | 2012 | 297 | 0.970 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 207 | 0.950 |
Why?
|
Vaccination | 13 | 2023 | 3278 | 0.920 |
Why?
|
Antigens, Neoplasm | 8 | 2021 | 1988 | 0.860 |
Why?
|
T-Lymphocytes | 19 | 2021 | 10180 | 0.850 |
Why?
|
Graft vs Host Disease | 15 | 2023 | 2957 | 0.800 |
Why?
|
Thalidomide | 5 | 2017 | 890 | 0.760 |
Why?
|
Tumor Microenvironment | 9 | 2023 | 3586 | 0.730 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 8 | 2023 | 903 | 0.730 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 21 | 2023 | 11524 | 0.710 |
Why?
|
Lymphocyte Activation | 19 | 2022 | 5524 | 0.680 |
Why?
|
Immunomodulation | 4 | 2018 | 541 | 0.680 |
Why?
|
Stem Cell Transplantation | 9 | 2018 | 1620 | 0.670 |
Why?
|
Cell Proliferation | 17 | 2020 | 10481 | 0.650 |
Why?
|
Transplantation Conditioning | 7 | 2020 | 1598 | 0.640 |
Why?
|
Transplantation, Autologous | 13 | 2023 | 2124 | 0.630 |
Why?
|
T-Lymphocytes, Regulatory | 10 | 2017 | 2988 | 0.620 |
Why?
|
Transplantation, Homologous | 11 | 2018 | 4776 | 0.600 |
Why?
|
Interleukin-12 | 4 | 2008 | 579 | 0.590 |
Why?
|
Remission Induction | 9 | 2017 | 2386 | 0.580 |
Why?
|
Antibodies, Monoclonal | 13 | 2016 | 9274 | 0.570 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2017 | 651 | 0.560 |
Why?
|
Dexamethasone | 5 | 2023 | 1951 | 0.560 |
Why?
|
Peptides | 6 | 2017 | 4409 | 0.530 |
Why?
|
Melphalan | 5 | 2019 | 431 | 0.510 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2019 | 314 | 0.490 |
Why?
|
Immune Tolerance | 4 | 2018 | 2258 | 0.490 |
Why?
|
Immunity, Cellular | 5 | 2019 | 1607 | 0.480 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 286 | 0.480 |
Why?
|
Lymphoma, B-Cell | 4 | 2021 | 931 | 0.470 |
Why?
|
Cell Communication | 4 | 2017 | 1621 | 0.450 |
Why?
|
Molecular Targeted Therapy | 5 | 2018 | 2727 | 0.450 |
Why?
|
Humans | 152 | 2023 | 744343 | 0.430 |
Why?
|
Recurrence | 12 | 2023 | 8340 | 0.430 |
Why?
|
Antigen Presentation | 7 | 2012 | 1284 | 0.420 |
Why?
|
Coculture Techniques | 7 | 2017 | 1341 | 0.420 |
Why?
|
Apoptosis | 11 | 2020 | 9727 | 0.420 |
Why?
|
Lymphocyte Transfusion | 2 | 2014 | 236 | 0.410 |
Why?
|
Bone Marrow | 3 | 2023 | 2948 | 0.410 |
Why?
|
Oligonucleotides | 2 | 2020 | 572 | 0.410 |
Why?
|
CD8-Positive T-Lymphocytes | 5 | 2022 | 4479 | 0.400 |
Why?
|
Cell Line, Tumor | 18 | 2020 | 16689 | 0.390 |
Why?
|
Stromal Cells | 1 | 2017 | 1355 | 0.390 |
Why?
|
MicroRNAs | 5 | 2020 | 3752 | 0.390 |
Why?
|
Carcinoembryonic Antigen | 1 | 2012 | 349 | 0.390 |
Why?
|
Antigens, CD | 5 | 2016 | 4026 | 0.390 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2012 | 1821 | 0.390 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2015 | 1157 | 0.370 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2007 | 648 | 0.370 |
Why?
|
Leukocytes, Mononuclear | 4 | 2017 | 1836 | 0.350 |
Why?
|
Oxidative Stress | 3 | 2017 | 3086 | 0.340 |
Why?
|
Cytotoxicity, Immunologic | 7 | 2017 | 1369 | 0.330 |
Why?
|
Reactive Oxygen Species | 6 | 2017 | 2077 | 0.320 |
Why?
|
Granzymes | 1 | 2010 | 271 | 0.320 |
Why?
|
Virus Activation | 3 | 2019 | 319 | 0.310 |
Why?
|
Antineoplastic Agents | 13 | 2017 | 13695 | 0.310 |
Why?
|
Animals | 33 | 2022 | 168757 | 0.310 |
Why?
|
Neoplastic Stem Cells | 2 | 2013 | 1376 | 0.300 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 4 | 2020 | 1378 | 0.290 |
Why?
|
Interferon-gamma | 6 | 2017 | 3206 | 0.290 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 927 | 0.290 |
Why?
|
Kidney Neoplasms | 5 | 2007 | 4262 | 0.290 |
Why?
|
Transplantation Immunology | 3 | 2016 | 546 | 0.280 |
Why?
|
Killer Cells, Natural | 6 | 2016 | 2133 | 0.280 |
Why?
|
Immunologic Factors | 3 | 2018 | 1580 | 0.280 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2007 | 227 | 0.270 |
Why?
|
Th17 Cells | 1 | 2012 | 766 | 0.270 |
Why?
|
Flow Cytometry | 10 | 2015 | 5974 | 0.270 |
Why?
|
Immunophenotyping | 10 | 2013 | 1880 | 0.260 |
Why?
|
Breast Neoplasms | 14 | 2017 | 20822 | 0.260 |
Why?
|
Tumor Cells, Cultured | 12 | 2019 | 6314 | 0.260 |
Why?
|
Leukemia | 4 | 2016 | 1511 | 0.260 |
Why?
|
Neoplasms | 8 | 2016 | 21683 | 0.250 |
Why?
|
Pancreatic Neoplasms | 1 | 2022 | 5256 | 0.250 |
Why?
|
Anilides | 2 | 2017 | 408 | 0.240 |
Why?
|
Antigens, CD34 | 5 | 2016 | 657 | 0.230 |
Why?
|
B-Cell Maturation Antigen | 2 | 2022 | 140 | 0.230 |
Why?
|
Boronic Acids | 4 | 2014 | 965 | 0.230 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2020 | 8428 | 0.220 |
Why?
|
Mice | 21 | 2022 | 81183 | 0.220 |
Why?
|
Signal Transduction | 6 | 2017 | 23403 | 0.220 |
Why?
|
Drug Synergism | 6 | 2017 | 1792 | 0.220 |
Why?
|
Immunoenzyme Techniques | 3 | 2015 | 1799 | 0.210 |
Why?
|
Carcinoma, Renal Cell | 3 | 2007 | 3143 | 0.210 |
Why?
|
Whole-Body Irradiation | 2 | 2020 | 449 | 0.210 |
Why?
|
Th1-Th2 Balance | 2 | 2012 | 38 | 0.210 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 2 | 2014 | 134 | 0.210 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2017 | 491 | 0.210 |
Why?
|
Pyrazines | 4 | 2014 | 1230 | 0.210 |
Why?
|
Immune System | 2 | 2018 | 805 | 0.200 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 693 | 0.200 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 3768 | 0.200 |
Why?
|
Down-Regulation | 3 | 2019 | 3002 | 0.200 |
Why?
|
Cryptosporidiosis | 1 | 2021 | 60 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2017 | 987 | 0.190 |
Why?
|
Mice, SCID | 3 | 2016 | 2716 | 0.190 |
Why?
|
Hodgkin Disease | 3 | 2019 | 1415 | 0.190 |
Why?
|
Oncogene Proteins | 2 | 2016 | 749 | 0.190 |
Why?
|
Cell Differentiation | 10 | 2017 | 11483 | 0.190 |
Why?
|
Photopheresis | 1 | 2020 | 24 | 0.190 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2020 | 3557 | 0.190 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1381 | 0.180 |
Why?
|
Biomedical Research | 3 | 2010 | 3309 | 0.180 |
Why?
|
Vitamin D | 2 | 2012 | 3223 | 0.180 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1878 | 0.180 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 689 | 0.170 |
Why?
|
Blotting, Western | 4 | 2015 | 5179 | 0.170 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 323 | 0.170 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 4751 | 0.170 |
Why?
|
Hematopoietic Stem Cells | 6 | 2013 | 3386 | 0.170 |
Why?
|
Lymphocyte Culture Test, Mixed | 6 | 2009 | 517 | 0.170 |
Why?
|
Middle Aged | 49 | 2021 | 213383 | 0.170 |
Why?
|
Neurotoxicity Syndromes | 1 | 2023 | 290 | 0.170 |
Why?
|
Isoantigens | 2 | 2017 | 567 | 0.170 |
Why?
|
Female | 58 | 2021 | 380194 | 0.160 |
Why?
|
Cytarabine | 3 | 2019 | 692 | 0.160 |
Why?
|
Oxidation-Reduction | 4 | 2017 | 2187 | 0.160 |
Why?
|
Oligonucleotides, Antisense | 1 | 2020 | 433 | 0.160 |
Why?
|
Interleukin-2 | 3 | 2016 | 1904 | 0.160 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.160 |
Why?
|
Lymphoma | 5 | 2020 | 1877 | 0.160 |
Why?
|
Herpesvirus 6, Human | 1 | 2018 | 95 | 0.150 |
Why?
|
Vinblastine | 1 | 2019 | 502 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2017 | 5172 | 0.150 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2018 | 150 | 0.150 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2019 | 236 | 0.150 |
Why?
|
Forkhead Transcription Factors | 4 | 2017 | 1613 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 336 | 0.150 |
Why?
|
Cross-Priming | 1 | 2017 | 82 | 0.150 |
Why?
|
Perforin | 1 | 2017 | 168 | 0.150 |
Why?
|
Glutathione | 3 | 2015 | 589 | 0.150 |
Why?
|
Myelodysplastic Syndromes | 2 | 2020 | 1352 | 0.150 |
Why?
|
Fusion Proteins, bcr-abl | 2 | 2010 | 434 | 0.140 |
Why?
|
Aged | 34 | 2021 | 163280 | 0.140 |
Why?
|
JC Virus | 2 | 2014 | 85 | 0.140 |
Why?
|
Receptors, CCR7 | 2 | 2008 | 108 | 0.140 |
Why?
|
Galactosylceramides | 1 | 2017 | 92 | 0.140 |
Why?
|
Mitoxantrone | 3 | 2017 | 152 | 0.140 |
Why?
|
Male | 48 | 2021 | 350118 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2017 | 286 | 0.140 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 1998 | 264 | 0.140 |
Why?
|
Adult | 43 | 2020 | 214055 | 0.140 |
Why?
|
Retroviridae | 1 | 2019 | 914 | 0.140 |
Why?
|
Dacarbazine | 1 | 2019 | 566 | 0.140 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2015 | 431 | 0.140 |
Why?
|
Tretinoin | 1 | 2019 | 517 | 0.140 |
Why?
|
Neoplasm, Residual | 2 | 2020 | 973 | 0.130 |
Why?
|
Polydeoxyribonucleotides | 2 | 2010 | 127 | 0.130 |
Why?
|
HMGB1 Protein | 1 | 2017 | 133 | 0.130 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5686 | 0.130 |
Why?
|
Doxorubicin | 4 | 2019 | 2234 | 0.130 |
Why?
|
Glioblastoma | 2 | 2023 | 3481 | 0.130 |
Why?
|
Pyridines | 2 | 2017 | 2825 | 0.130 |
Why?
|
Cell Survival | 5 | 2016 | 5882 | 0.130 |
Why?
|
Ribonuclease III | 1 | 2017 | 275 | 0.130 |
Why?
|
Bone Marrow Transplantation | 3 | 2017 | 2765 | 0.130 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 246 | 0.130 |
Why?
|
Tumor Escape | 1 | 2018 | 349 | 0.130 |
Why?
|
Etoposide | 3 | 2017 | 641 | 0.130 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2085 | 0.130 |
Why?
|
Hybrid Cells | 2 | 2005 | 441 | 0.130 |
Why?
|
Chemokine CXCL12 | 1 | 2017 | 464 | 0.120 |
Why?
|
Gene Silencing | 3 | 2017 | 1538 | 0.120 |
Why?
|
Immunoblotting | 3 | 2014 | 1682 | 0.120 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2010 | 220 | 0.120 |
Why?
|
Virus Diseases | 1 | 2001 | 711 | 0.120 |
Why?
|
Antigen-Presenting Cells | 1 | 2018 | 973 | 0.120 |
Why?
|
Response Elements | 1 | 2016 | 312 | 0.120 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2016 | 535 | 0.120 |
Why?
|
NADP | 1 | 2015 | 226 | 0.120 |
Why?
|
Yttrium Radioisotopes | 1 | 2015 | 93 | 0.120 |
Why?
|
Graft vs Leukemia Effect | 1 | 2014 | 111 | 0.120 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2915 | 0.120 |
Why?
|
Fetal Blood | 2 | 2019 | 1318 | 0.120 |
Why?
|
Transplantation | 1 | 2015 | 217 | 0.120 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 310 | 0.120 |
Why?
|
Lymphoma, T-Cell | 1 | 2016 | 299 | 0.120 |
Why?
|
Leukapheresis | 3 | 2003 | 131 | 0.120 |
Why?
|
Janus Kinase 2 | 1 | 2017 | 528 | 0.120 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2019 | 871 | 0.110 |
Why?
|
Necrosis | 2 | 2015 | 1643 | 0.110 |
Why?
|
Cells, Cultured | 7 | 2014 | 19229 | 0.110 |
Why?
|
Antigens, CD1 | 3 | 2008 | 437 | 0.110 |
Why?
|
Interleukin-10 | 3 | 2009 | 1200 | 0.110 |
Why?
|
Parathyroid Hormone | 2 | 2012 | 1801 | 0.110 |
Why?
|
Fowlpox virus | 1 | 2012 | 20 | 0.110 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1041 | 0.110 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 789 | 0.110 |
Why?
|
Treatment Outcome | 18 | 2018 | 63114 | 0.110 |
Why?
|
PPAR delta | 1 | 2012 | 43 | 0.110 |
Why?
|
STAT3 Transcription Factor | 1 | 2017 | 873 | 0.110 |
Why?
|
Arabinonucleosides | 1 | 2012 | 35 | 0.110 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2013 | 288 | 0.110 |
Why?
|
Adenine Nucleotides | 1 | 2012 | 121 | 0.100 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 3 | 2003 | 272 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2001 | 1401 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 570 | 0.100 |
Why?
|
Interleukin-4 | 3 | 2014 | 1147 | 0.100 |
Why?
|
STAT Transcription Factors | 1 | 2012 | 182 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 3 | 2012 | 1838 | 0.100 |
Why?
|
Ifosfamide | 2 | 2003 | 228 | 0.100 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 140 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2021 | 2540 | 0.100 |
Why?
|
Combined Modality Therapy | 6 | 2016 | 8642 | 0.100 |
Why?
|
Deglutition Disorders | 1 | 2017 | 605 | 0.100 |
Why?
|
Hematologic Diseases | 2 | 2012 | 498 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1142 | 0.100 |
Why?
|
Transcriptional Activation | 1 | 2017 | 1783 | 0.090 |
Why?
|
Viral Proteins | 1 | 2018 | 1900 | 0.090 |
Why?
|
RNA, Messenger | 3 | 2015 | 13033 | 0.090 |
Why?
|
Cytokines | 3 | 2017 | 7322 | 0.090 |
Why?
|
Lymphocyte Depletion | 2 | 2006 | 608 | 0.090 |
Why?
|
Pyrimidines | 2 | 2019 | 2942 | 0.090 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2010 | 71 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 2 | 2012 | 2849 | 0.090 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2011 | 349 | 0.090 |
Why?
|
Radiotherapy | 1 | 2017 | 1533 | 0.090 |
Why?
|
Mitogens | 1 | 2010 | 232 | 0.090 |
Why?
|
Survival Analysis | 7 | 2019 | 10252 | 0.090 |
Why?
|
Chromosome Aberrations | 1 | 2016 | 1813 | 0.090 |
Why?
|
Antibodies, Protozoan | 1 | 2010 | 253 | 0.090 |
Why?
|
Sirolimus | 1 | 2017 | 1564 | 0.090 |
Why?
|
Radiation Injuries | 1 | 2017 | 1180 | 0.090 |
Why?
|
Multiple Organ Failure | 2 | 2010 | 390 | 0.090 |
Why?
|
Brain Neoplasms | 2 | 2023 | 8863 | 0.090 |
Why?
|
Transduction, Genetic | 1 | 2012 | 913 | 0.090 |
Why?
|
Maximum Tolerated Dose | 3 | 2017 | 892 | 0.080 |
Why?
|
Mice, Inbred C57BL | 5 | 2019 | 21827 | 0.080 |
Why?
|
Antigens, Protozoan | 1 | 2010 | 322 | 0.080 |
Why?
|
Cell Division | 3 | 2012 | 4568 | 0.080 |
Why?
|
Metabolic Networks and Pathways | 1 | 2012 | 783 | 0.080 |
Why?
|
Up-Regulation | 1 | 2017 | 4217 | 0.080 |
Why?
|
Cell Separation | 3 | 2016 | 1751 | 0.080 |
Why?
|
Survival Rate | 8 | 2015 | 12788 | 0.080 |
Why?
|
DNA Methylation | 2 | 2019 | 4286 | 0.080 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2005 | 329 | 0.080 |
Why?
|
Receptors, Immunologic | 1 | 2014 | 1423 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2022 | 9239 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2012 | 4386 | 0.070 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2649 | 0.070 |
Why?
|
Disease Models, Animal | 3 | 2019 | 18029 | 0.070 |
Why?
|
Isocoumarins | 1 | 2006 | 19 | 0.070 |
Why?
|
Authorship | 1 | 2010 | 271 | 0.070 |
Why?
|
Disease-Free Survival | 7 | 2015 | 6895 | 0.070 |
Why?
|
Fibrinolytic Agents | 2 | 2010 | 2158 | 0.070 |
Why?
|
Antimitotic Agents | 1 | 2006 | 30 | 0.070 |
Why?
|
Cell Polarity | 1 | 2010 | 645 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2948 | 0.070 |
Why?
|
Clone Cells | 1 | 2010 | 1692 | 0.070 |
Why?
|
Filgrastim | 2 | 2007 | 133 | 0.070 |
Why?
|
Immunocompromised Host | 2 | 2021 | 847 | 0.070 |
Why?
|
Nuclear Proteins | 2 | 2012 | 5853 | 0.070 |
Why?
|
Granulocyte Precursor Cells | 1 | 2004 | 43 | 0.060 |
Why?
|
Chronic Disease | 5 | 2023 | 9146 | 0.060 |
Why?
|
Conflict of Interest | 1 | 2010 | 544 | 0.060 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4149 | 0.060 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 1596 | 0.060 |
Why?
|
Bone Marrow Cells | 3 | 2004 | 2513 | 0.060 |
Why?
|
Lymphocyte Count | 3 | 2016 | 793 | 0.060 |
Why?
|
Interleukin-7 | 1 | 2005 | 142 | 0.060 |
Why?
|
Fatty Acids | 1 | 2012 | 1809 | 0.060 |
Why?
|
Tissue Donors | 3 | 2018 | 2240 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5535 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 9959 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2014 | 3200 | 0.060 |
Why?
|
Disclosure | 1 | 2010 | 736 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2021 | 57776 | 0.060 |
Why?
|
Gene Expression | 1 | 2017 | 7799 | 0.060 |
Why?
|
Drug Industry | 1 | 2010 | 746 | 0.060 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2009 | 685 | 0.060 |
Why?
|
Neoplasms, Experimental | 2 | 2019 | 1276 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6538 | 0.060 |
Why?
|
Young Adult | 11 | 2019 | 56430 | 0.060 |
Why?
|
Clinical Trials as Topic | 4 | 2014 | 7913 | 0.060 |
Why?
|
Case-Control Studies | 4 | 2015 | 21746 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2942 | 0.060 |
Why?
|
Antibody Formation | 2 | 2005 | 1402 | 0.050 |
Why?
|
Glucocorticoids | 4 | 2018 | 2107 | 0.050 |
Why?
|
Th1 Cells | 1 | 2008 | 1057 | 0.050 |
Why?
|
Genetic Vectors | 1 | 2012 | 3420 | 0.050 |
Why?
|
Sterilization | 1 | 2003 | 133 | 0.050 |
Why?
|
Drug Administration Schedule | 5 | 2013 | 4933 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2005 | 669 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2016 | 7722 | 0.050 |
Why?
|
Lymphocytes | 2 | 2023 | 2617 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 391 | 0.050 |
Why?
|
Mitosis | 1 | 2006 | 1208 | 0.050 |
Why?
|
Pentostatin | 1 | 2020 | 26 | 0.050 |
Why?
|
K562 Cells | 3 | 2010 | 634 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4554 | 0.050 |
Why?
|
Phytohemagglutinins | 1 | 2000 | 170 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2000 | 112 | 0.050 |
Why?
|
Transcription Factors | 2 | 2012 | 12208 | 0.050 |
Why?
|
Mice, Inbred BALB C | 4 | 2013 | 6386 | 0.050 |
Why?
|
Pancreatitis | 1 | 2007 | 1092 | 0.050 |
Why?
|
Idarubicin | 1 | 2019 | 62 | 0.050 |
Why?
|
Antibodies | 1 | 2008 | 2460 | 0.040 |
Why?
|
Kidney Diseases | 1 | 2011 | 2149 | 0.040 |
Why?
|
Salvage Therapy | 2 | 2017 | 1275 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2002 | 623 | 0.040 |
Why?
|
Hypersensitivity, Delayed | 1 | 2000 | 484 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2021 | 380 | 0.040 |
Why?
|
U937 Cells | 1 | 2019 | 268 | 0.040 |
Why?
|
Prednisone | 2 | 2018 | 1574 | 0.040 |
Why?
|
Follow-Up Studies | 6 | 2022 | 39050 | 0.040 |
Why?
|
Foscarnet | 1 | 2018 | 38 | 0.040 |
Why?
|
Periodicals as Topic | 1 | 2010 | 1432 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2019 | 9734 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 2 | 2013 | 2505 | 0.040 |
Why?
|
Bacterial Vaccines | 1 | 2001 | 403 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2001 | 588 | 0.040 |
Why?
|
Skin Tests | 1 | 2000 | 613 | 0.040 |
Why?
|
Vidarabine | 1 | 2019 | 345 | 0.040 |
Why?
|
Steroids | 1 | 2023 | 930 | 0.040 |
Why?
|
Contrast Media | 1 | 2011 | 5300 | 0.040 |
Why?
|
Treatment Failure | 2 | 2020 | 2618 | 0.040 |
Why?
|
Cyclosporine | 1 | 2020 | 786 | 0.040 |
Why?
|
Thrombopoietin | 1 | 2019 | 225 | 0.040 |
Why?
|
Chimerism | 1 | 2018 | 158 | 0.040 |
Why?
|
Models, Biological | 2 | 2012 | 9583 | 0.040 |
Why?
|
Methotrexate | 2 | 2020 | 1727 | 0.040 |
Why?
|
Herpesvirus 8, Human | 1 | 1999 | 258 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 2971 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2000 | 881 | 0.040 |
Why?
|
Heartburn | 1 | 2017 | 68 | 0.040 |
Why?
|
Tacrolimus | 1 | 2020 | 743 | 0.040 |
Why?
|
Glutamate-Cysteine Ligase | 1 | 2016 | 25 | 0.040 |
Why?
|
Th2 Cells | 1 | 2001 | 1061 | 0.040 |
Why?
|
Mutation | 2 | 2019 | 29786 | 0.040 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2016 | 107 | 0.030 |
Why?
|
Benzylamines | 1 | 2017 | 223 | 0.030 |
Why?
|
Cyclin D2 | 1 | 2016 | 101 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2007 | 6622 | 0.030 |
Why?
|
Phenotype | 3 | 2011 | 16365 | 0.030 |
Why?
|
Protein Binding | 1 | 2008 | 9386 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 249 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9648 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3772 | 0.030 |
Why?
|
Ikaros Transcription Factor | 1 | 2017 | 217 | 0.030 |
Why?
|
Autoimmune Diseases | 1 | 2007 | 2133 | 0.030 |
Why?
|
Mediastinum | 1 | 2017 | 267 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2011 | 10943 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 601 | 0.030 |
Why?
|
Viral Vaccines | 1 | 2001 | 636 | 0.030 |
Why?
|
Transcription Factor RelA | 1 | 2016 | 275 | 0.030 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 307 | 0.030 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 91 | 0.030 |
Why?
|
Quality of Life | 1 | 2016 | 12804 | 0.030 |
Why?
|
Mycosis Fungoides | 1 | 2016 | 163 | 0.030 |
Why?
|
Fatigue | 2 | 2013 | 1531 | 0.030 |
Why?
|
Antigens, CD1d | 2 | 2008 | 220 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 610 | 0.030 |
Why?
|
Staphylococcus aureus | 1 | 2003 | 1451 | 0.030 |
Why?
|
Computational Biology | 2 | 2017 | 3521 | 0.030 |
Why?
|
Neutrophils | 2 | 2017 | 3719 | 0.030 |
Why?
|
Diarrhea | 1 | 2021 | 1348 | 0.030 |
Why?
|
Acute Disease | 2 | 2017 | 7149 | 0.030 |
Why?
|
Immunity | 1 | 2000 | 1012 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11124 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2011 | 13815 | 0.030 |
Why?
|
Cohort Studies | 5 | 2019 | 40561 | 0.030 |
Why?
|
Natural Killer T-Cells | 1 | 2017 | 316 | 0.030 |
Why?
|
Pulmonary Heart Disease | 1 | 1993 | 36 | 0.030 |
Why?
|
Chile | 1 | 2013 | 237 | 0.030 |
Why?
|
Mice, Nude | 2 | 2010 | 3689 | 0.030 |
Why?
|
United States | 3 | 2021 | 69872 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2004 | 11366 | 0.030 |
Why?
|
Carcinoma | 2 | 2002 | 2375 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2014 | 741 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 40075 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2012 | 356 | 0.030 |
Why?
|
Epoxy Compounds | 1 | 2012 | 136 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20129 | 0.030 |
Why?
|
Cryopreservation | 1 | 2016 | 670 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 526 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2016 | 1097 | 0.020 |
Why?
|
Cadherins | 1 | 2016 | 907 | 0.020 |
Why?
|
Dioxygenases | 1 | 2013 | 316 | 0.020 |
Why?
|
Luciferases | 1 | 2013 | 733 | 0.020 |
Why?
|
Triiodobenzoic Acids | 1 | 2011 | 124 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2959 | 0.020 |
Why?
|
Israel | 1 | 2013 | 796 | 0.020 |
Why?
|
Telomerase | 1 | 2016 | 730 | 0.020 |
Why?
|
Drug Resistance | 2 | 2011 | 1609 | 0.020 |
Why?
|
Adenine | 1 | 2016 | 936 | 0.020 |
Why?
|
Cell Culture Techniques | 3 | 2004 | 1678 | 0.020 |
Why?
|
beta Catenin | 1 | 2016 | 1059 | 0.020 |
Why?
|
Protein Subunits | 1 | 2014 | 959 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2559 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2016 | 606 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2012 | 905 | 0.020 |
Why?
|
Observation | 1 | 2011 | 312 | 0.020 |
Why?
|
Glucocorticoid-Induced TNFR-Related Protein | 1 | 2009 | 42 | 0.020 |
Why?
|
Myelopoiesis | 1 | 2010 | 133 | 0.020 |
Why?
|
Paclitaxel | 3 | 2002 | 1708 | 0.020 |
Why?
|
Prognosis | 3 | 2018 | 29063 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2011 | 272 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8324 | 0.020 |
Why?
|
Viral Load | 1 | 2018 | 3299 | 0.020 |
Why?
|
Sensation Disorders | 1 | 2010 | 155 | 0.020 |
Why?
|
Prospective Studies | 3 | 2023 | 53288 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2012 | 657 | 0.020 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2009 | 200 | 0.020 |
Why?
|
Biopolymers | 1 | 2009 | 189 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2009 | 315 | 0.020 |
Why?
|
Neutropenia | 1 | 2013 | 895 | 0.020 |
Why?
|
Polyneuropathies | 1 | 2009 | 137 | 0.020 |
Why?
|
Arsenicals | 1 | 2008 | 124 | 0.020 |
Why?
|
Piperidines | 1 | 2016 | 1602 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2011 | 1588 | 0.020 |
Why?
|
Placebos | 1 | 2012 | 1676 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2038 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 3701 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2001 | 4665 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2455 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2010 | 893 | 0.020 |
Why?
|
India | 1 | 2013 | 2197 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 3920 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2009 | 595 | 0.020 |
Why?
|
T-Box Domain Proteins | 1 | 2009 | 471 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3505 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1179 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2010 | 18111 | 0.020 |
Why?
|
Oxides | 1 | 2008 | 405 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2014 | 4420 | 0.020 |
Why?
|
Graft vs Tumor Effect | 1 | 2006 | 72 | 0.020 |
Why?
|
ADP Ribose Transferases | 1 | 1986 | 90 | 0.020 |
Why?
|
Exotoxins | 1 | 1986 | 119 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1993 | 934 | 0.020 |
Why?
|
HLA-DR Antigens | 2 | 1999 | 645 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2017 | 77449 | 0.020 |
Why?
|
Pyrazoles | 1 | 2016 | 1972 | 0.020 |
Why?
|
Oligopeptides | 1 | 2011 | 1189 | 0.020 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1993 | 949 | 0.020 |
Why?
|
Protein Multimerization | 1 | 2010 | 970 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2009 | 791 | 0.020 |
Why?
|
Thiazoles | 1 | 2012 | 1483 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2017 | 2958 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2007 | 769 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5867 | 0.020 |
Why?
|
Protein Transport | 1 | 2010 | 1988 | 0.020 |
Why?
|
Pneumonia | 1 | 2016 | 2133 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 840 | 0.020 |
Why?
|
Adolescent | 6 | 2012 | 85781 | 0.010 |
Why?
|
Graft Rejection | 1 | 1997 | 4397 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2011 | 3846 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2006 | 730 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2000 | 4838 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 333 | 0.010 |
Why?
|
Catheterization | 2 | 2003 | 1470 | 0.010 |
Why?
|
Physician's Role | 1 | 2010 | 943 | 0.010 |
Why?
|
Virulence Factors | 1 | 1986 | 509 | 0.010 |
Why?
|
Pain | 2 | 2010 | 4986 | 0.010 |
Why?
|
Thiotepa | 1 | 2002 | 66 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2007 | 1641 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2010 | 2382 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2001 | 82 | 0.010 |
Why?
|
Graft Survival | 1 | 2012 | 3737 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 370 | 0.010 |
Why?
|
Child, Preschool | 4 | 2010 | 41006 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2009 | 2007 | 0.010 |
Why?
|
Macrophages | 1 | 1996 | 5655 | 0.010 |
Why?
|
NF-kappa B | 1 | 2010 | 2499 | 0.010 |
Why?
|
Plasmacytoma | 1 | 2002 | 183 | 0.010 |
Why?
|
Neoplasm Metastasis | 2 | 2002 | 4851 | 0.010 |
Why?
|
Immunization Schedule | 1 | 2002 | 221 | 0.010 |
Why?
|
Risk Factors | 3 | 2019 | 72290 | 0.010 |
Why?
|
Cell Line | 2 | 2008 | 15997 | 0.010 |
Why?
|
Blood Cells | 1 | 2003 | 309 | 0.010 |
Why?
|
Bilirubin | 1 | 2002 | 425 | 0.010 |
Why?
|
Lung Neoplasms | 2 | 2017 | 13102 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 1986 | 931 | 0.010 |
Why?
|
Immunization | 1 | 2005 | 1256 | 0.010 |
Why?
|
Microtubules | 1 | 2006 | 1090 | 0.010 |
Why?
|
Ascites | 1 | 2002 | 344 | 0.010 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 497 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 11031 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15226 | 0.010 |
Why?
|
Mitochondria | 1 | 2012 | 3520 | 0.010 |
Why?
|
Regeneration | 1 | 2008 | 1485 | 0.010 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2002 | 415 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2005 | 1470 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6234 | 0.010 |
Why?
|
Carboplatin | 1 | 2002 | 801 | 0.010 |
Why?
|
Pseudomonas aeruginosa | 1 | 1986 | 1219 | 0.010 |
Why?
|
Aging | 1 | 1997 | 8664 | 0.010 |
Why?
|
Immunologic Memory | 1 | 2005 | 1348 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12026 | 0.010 |
Why?
|
Infant | 3 | 2010 | 35136 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2004 | 3144 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2274 | 0.010 |
Why?
|
Progesterone | 1 | 2002 | 776 | 0.010 |
Why?
|
Antigens, Surface | 1 | 2001 | 1663 | 0.010 |
Why?
|
Fluorouracil | 1 | 2002 | 1619 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2004 | 2699 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2000 | 880 | 0.010 |
Why?
|
Child | 4 | 2010 | 77709 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2002 | 2242 | 0.010 |
Why?
|
Stem Cell Factor | 1 | 1996 | 219 | 0.010 |
Why?
|
HeLa Cells | 1 | 2001 | 3128 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13284 | 0.010 |
Why?
|
Estrogens | 1 | 2002 | 1566 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 20947 | 0.010 |
Why?
|
DNA, Viral | 1 | 1999 | 2225 | 0.010 |
Why?
|
Biopsy | 1 | 2002 | 6756 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2010 | 25625 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2002 | 12245 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2002 | 12354 | 0.000 |
Why?
|
Liver | 1 | 2002 | 7474 | 0.000 |
Why?
|
HIV Infections | 1 | 2012 | 16718 | 0.000 |
Why?
|
Nucleotidyltransferases | 1 | 1986 | 220 | 0.000 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 1986 | 440 | 0.000 |
Why?
|
Pulmonary Artery | 1 | 1993 | 1912 | 0.000 |
Why?
|
Neutralization Tests | 1 | 1986 | 758 | 0.000 |
Why?
|
Antibody Specificity | 1 | 1986 | 1095 | 0.000 |
Why?
|
Epitopes | 1 | 1986 | 2571 | 0.000 |
Why?
|